Syndax Pharmaceuticals (SNDX) to Release Quarterly Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to announce its earnings results after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of ($1.13) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million for the quarter. The company’s revenue was up 3499999990.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.64) EPS. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syndax Pharmaceuticals Trading Up 0.6 %

Shares of SNDX opened at $18.98 on Friday. The company has a market cap of $1.62 billion, a PE ratio of -5.62 and a beta of 0.92. The stock has a 50-day moving average price of $19.11 and a 200-day moving average price of $20.33. Syndax Pharmaceuticals has a 12-month low of $13.14 and a 12-month high of $25.34.

Analysts Set New Price Targets

SNDX has been the subject of a number of research analyst reports. Bank of America lifted their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. UBS Group initiated coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 price target for the company. Barclays lifted their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th. JPMorgan Chase & Co. decreased their price objective on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, Citigroup raised their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.90.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).